Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS+: Long-term Follow-up of Subcutaneous Efgartigimod PH20 in Pemphigus
jRCT2031210277Active, not recruiting
- Sponsor
- argenx
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by argenx. Primary endpoints: Treatment-emergent adverse events, Adverse events of special interest and 5 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on jRCT2031210277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210277.